MEIRAGTX HOLDINGS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.01 USD | -4.57% |
|
-12.57% | -28.63% |
Financials (USD)
| Sales 2024 * | 55.77M | Sales 2025 * | 273M | Capitalization | 322M |
|---|---|---|---|---|---|
| Net income 2024 * | -126M | Net income 2025 * | 133M | EV / Sales 2024 * | 5.77 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.18 x |
| P/E ratio 2024 * |
-2.84
x | P/E ratio 2025 * |
3.77
x | Employees | 422 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.67% |
More Fundamentals
* Assessed data
More news
Latest transcript on MeiraGTx Holdings plc
More recommendations
More press releases
| 1 day | -4.57% | ||
| 1 week | -12.57% | ||
| Current month | -17.46% | ||
| 1 month | -19.19% | ||
| 3 months | -16.78% | ||
| 6 months | +24.63% | ||
| Current year | -28.63% |
1 week
4.89
5.65
1 month
4.896.72
Current year
4.897.57
1 year
3.498.35
3 years
3.4924.89
5 years
3.4930.23
10 years
3.4930.23
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Giroux
FOU | Founder | 61 | 15-03-19 |
| Chief Executive Officer | 59 | 15-03-19 | |
Robert Zeldin
CTO | Chief Tech/Sci/R&D Officer | 61 | 20-08-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Debra Yu
BRD | Director/Board Member | 59 | 22-04-24 |
Thomas Shenk
BRD | Director/Board Member | 77 | 15-05-31 |
Keith Harris
CHM | Chairman | 71 | 15-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.00% | 9 M€ | +4.47% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 5.01 | -4.57% | 235,243 |
| 24-04-17 | 5.25 | -2.96% | 155,067 |
| 24-04-16 | 5.41 | -1.10% | 128,664 |
| 24-04-15 | 5.47 | -1.62% | 110,388 |
| 24-04-12 | 5.56 | -2.97% | 140,985 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogrenâs Syndrome; AAV-GAD for the treatment of Parkinsonâs Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.01
USD
Average target price
21.6
USD
Spread / Average Target
+331.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.63% | 322M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -2.18% | 21.66B | |
| -18.35% | 20.77B | |
| -8.77% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- MGTX Stock
